Form 4: Neuronetics Director Sasha Cucuz Increases Stake

Neuronetics Director Sasha Cucuz acquired 6,410 shares of common stock in lieu of a cash retainer, increasing beneficial ownership.

Summary

• Sasha Cucuz, a Director of Neuronetics, Inc. (STIM), acquired 6,410 shares of common stock.
• The acquisition occurred on October 20, 2025, and was reported on October 22, 2025.
• These shares were received as a restricted stock unit (RSU) award, which vested immediately upon grant, in lieu of a cash retainer under the Issuer's non-employee directors compensation plan.
• The transaction price for these shares was $0.
• Following this transaction, Sasha Cucuz directly beneficially owns 1,512,798 shares of common stock.
• Additionally, 2,042 shares are indirectly owned by Greybrook Realty Partners Inc. and 516,084 shares by Greybrook Health Inc.

Sentiment

Score: 6

Explanation: Slightly positive. A director choosing equity over cash indicates confidence and better alignment with shareholder interests, though it's a routine compensation event.

Positives

• A director elected to receive equity instead of cash, aligning their interests more closely with shareholders.
• The immediate vesting of the RSU award indicates a direct increase in the director's beneficial ownership.

Risks

• Form 4 filings primarily report insider transactions and do not typically detail company-specific risks.

Future Outlook

This Form 4 filing reports a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

The practice of compensating non-employee directors with equity, such as restricted stock units, is a common corporate governance practice across various industries. It aims to align the interests of directors with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• Compensating non-employee directors with equity, specifically RSUs, is a widely adopted practice, consistent with corporate governance best practices in the U.S. and globally.
• Many companies, including peers in the medical device and healthcare technology sectors, utilize similar equity-based compensation plans to attract and retain qualified independent directors and foster long-term value creation.
• The $0 transaction price for the RSU grant is standard for equity compensation awards where shares are granted in lieu of cash or as part of a compensation package.

Corporate Governance

Related Party Transactions

• Sasha Cucuz's indirect beneficial ownership through Greybrook Realty Partners Inc. (2,042 shares) and Greybrook Health Inc. (516,084 shares) indicates existing relationships that could be considered related party interests.

Stakeholder Impact

• Shareholders: Potentially positive, as a director's increased equity stake can signal confidence in the company's future and better align management incentives with shareholder returns.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director received equity as part of their compensation. While the director's choice to take shares over cash can be seen as a minor positive signal of confidence, it does not provide sufficient new information about the company's operational performance, financial health, or strategic direction to warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, pending further comprehensive financial disclosures.

Keywords

Neuronetics, STIM, Sasha Cucuz, Insider Transaction, Form 4, Director Compensation, Common Stock, Restricted Stock Unit, Equity Compensation